In calendar year 2021, 340B covered entities purchased $43.9 billion in covered outpatient drugs under the 340B Program. This program enables safety-net providers to stretch scarce federal resources as far as possible, reaching more eligible patients and providing more comprehensive services for the communities that they serve. The information below details the aggregate 340B purchases by covered entity type in 2021.
| Entity Type | 2021 Total Purchases |
|---|---|
| Disproportionate Share Hospitals | $34,288,472,705 |
| Health Center Programs | $2,215,221,250 |
| Children's Hospitals | $1,330,248,212 |
| Rural Referral Centers | $1,174,151,155 |
| Ryan White HIV/AIDS Program Part A | $1,151,719,110 |
| Sexually Transmitted Disease Clinics | $871,036,833 |
| Critical Access Hospitals | $620,923,559 |
| Ryan White HIV/AIDS Program Part C | $519,299,391 |
| Sole Community Hospitals | $451,594,319 |
| Free-standing Cancer Centers | $304,098,033 |
| Ryan White HIV/AIDS Program Part B | $234,735,497 |
| Ryan White Part B AIDS Drug Assistance Program (ADAP) Direct Purchase Option | $230,807,198 |
| Comprehensive Hemophilia Treatment Centers | $192,106,843 |
| Federally Qualified Health Center Look-Alike Program | $173,025,319 |
| Family Planning Clinics | $74,912,338 |
| Ryan White HIV/AIDS Program Part D | $43,419,350 |
| Tribal Contract/Compact with IHS (P.L. 93-638) | $30,973,328 |
| Tuberculosis Clinics | $4,278,525 |
| Urban Indian Hospitals | $1,154,612 |
| Black Lung Clinics | $189,963 |
| Ryan White Part B ADAP Rebate Option | $23,336 |
| Native Hawaiian Heath Care Programs | $23,305 |
| Total | $43,912,414,182 |
Source: 340B Prime Vendor Program, August 12, 2022
Note: These purchase data are provided by the 340B Prime Vendor Program and do not capture the entire universe of 340B Program purchases (e.g., the Prime Vendor Program does not collect all direct purchases). The Prime Vendor Program was established pursuant to section 340B(a)(8) of the Public Health Service Act for price negotiation, distribution facilitation, and other activities in support of the 340B Drug Pricing Program. It is managed by Apexus through a contract with the Health Resources and Services Administration. These figures are accurate as of Aug. 12, 2022. The purchase data provided is a culmination of transactional data captured by the Prime Vendor Program at a given point in time. The totals reflected in this chart may change, as the 340B Prime Vendor Program is constantly reviewing and updating the data as transactions occur, and there are times when adjustments to invoices are made which impact the total purchases reported. Entity organizations are defined at section 340B(a)(4) of the Public Health Service Act.